Method for obtaining activated lymphocytes, comprising at least the steps of a. providing antigen-presenting cells displaying disease-associated antigens, wherein the antigen-presenting cells are obtained by the following steps of i. providing an extracorporeal sample of mammalian disease-effector cells and subjecting said disease-effector cells to apoptotic agents to release disease-associated antigens or providing isolated disease-associated antigens, ii. providing an extracorporeal quantity of a mammalian subject's blood sample comprising monocytes separately from step i), iii. activating said monocytes to induce their differentiation into immuno-stimulatory autologous APCs in the absence of apoptotic agents separately from step i), iv. combining said immuno-stimulatory autologous APCs of step iii) with said apoptotic disease-effector cells or isolated disease-associated antigens of step i); wherein alternatively, step iv. can be performed prior to performing step iii. such that said apoptotic disease effector cells or isolated disease-associated antigens of step i) are combined with said monocytes of step ii), followed by activation of said monocytes in the mixture to induce their differentiation into immuno-stimulatory autologous APCs in the absence of apoptotic agents. b. providing an extracorporeal quantity comprising CD8 + T-lymphocytes or genetically modified T-lymphocytes; c. combining said antigen-presenting cells displaying disease-associated antigens of step a. with said lymphocytes of step b); and d. incubating the mixture of step c), wherein the antigen-presenting cells displaying disease-associated antigens will activate the lymphocytes to proliferate. a. providing antigen-presenting cells displaying disease-associated antigens, wherein the antigen-presenting cells are obtained by the following steps of i. providing an extracorporeal sample of mammalian disease-effector cells and subjecting said disease-effector cells to apoptotic agents to release disease-associated antigens or providing isolated disease-associated antigens, ii. providing an extracorporeal quantity of a mammalian subject's blood sample comprising monocytes separately from step i), iii. activating said monocytes to induce their differentiation into immuno-stimulatory autologous APCs in the absence of apoptotic agents separately from step i), iv. combining said immuno-stimulatory autologous APCs of step iii) with said apoptotic disease-effector cells or isolated disease-associated antigens of step i); wherein alternatively, step iv. can be performed prior to performing step iii. such that said apoptotic disease effector cells or isolated disease-associated antigens of step i) are combined with said monocytes of step ii), followed by activation of said monocytes in the mixture to induce their differentiation into immuno-stimulatory autologous APCs in the absence of apoptotic agents. i. providing an extracorporeal sample of mammalian disease-effector cells and subjecting said disease-effector cells to apoptotic agents to release disease-associated antigens or providing isolated disease-associated antigens, ii. providing an extracorporeal quantity of a mammalian subject's blood sample comprising monocytes separately from step i), iii. activating said monocytes to induce their differentiation into immuno-stimulatory autologous APCs in the absence of apoptotic agents separately from step i), iv. combining said immuno-stimulatory autologous APCs of step iii) with said apoptotic disease-effector cells or isolated disease-associated antigens of step i); wherein alternatively, step iv. can be performed prior to performing step iii. such that said apoptotic disease effector cells or isolated disease-associated antigens of step i) are combined with said monocytes of step ii), followed by activation of said monocytes in the mixture to induce their differentiation into immuno-stimulatory autologous APCs in the absence of apoptotic agents. b. providing an extracorporeal quantity comprising CD8 + T-lymphocytes or genetically modified T-lymphocytes; c. combining said antigen-presenting cells displaying disease-associated antigens of step a. with said lymphocytes of step b); and d. incubating the mixture of step c), wherein the antigen-presenting cells displaying disease-associated antigens will activate the lymphocytes to proliferate.